期刊文献+

MALDI-TOF-MS技术对HBV耐药基因突变检测的价值 被引量:2

原文传递
导出
摘要 目的:探讨MALDI-TOF-MS技术对乙型肝炎病毒(HBV)耐药基因突变检测的价值。方法:依据HBV、HCV基因组多态性及基因突变现有研究结果,选择靶区域,筛选突变位点,MassARRAY Assay Design软件设计iPLEX引物,按iPLEX反应的操作说明进行PCR扩增、SAP反应、引物延伸、脱盐、点样,MALDI-TOF-MS采集、分析iPLEX反应物的数据,判读基因变异位点。收集本院抗病毒药物单药或多药耐药患者血清30份,将MALDI-TOF-MS技术判读基因变异位点进行DNA测序,将结果与MALDI-TOF-MS检测结果进行对比。结果:利用MALDI-TOF-MS技术一次性可检测30份血清样本的HBV基因突变,在30份样本中,5份检测结果不一致,其中2份是MALDI-TOF-MS技术未检测到的基因突变点,1份是2个检测位点不一致。结论:MALDI-TOF-MS技术具有灵敏度高、准确度高及分辨率高等特点,为生命科学等领域提供了一种强有力的分析测试手段。
作者 李华建
出处 《中国普通外科杂志》 CAS CSCD 北大核心 2013年第5期658-660,共3页 China Journal of General Surgery
基金 河北省廊坊市科学技术研究与发展计划自筹经费资助项目(20011013077)
  • 相关文献

参考文献6

二级参考文献11

  • 1马军,段芳龄.亚洲太平洋地区慢性乙型肝炎处理的共识(2005年最新报告)[J].胃肠病学和肝病学杂志,2005,14(5):436-439. 被引量:100
  • 2Zoulim F. Detection of hepatitis B virus resistance to antivirals. J Clin Virol, 2001,21:243-253.
  • 3Matthews GV, Bartholomeusz A, Locarnini S. Characteristics of drug resistant HBV in an international collaborative study of HIV-HBV-infected individuals on extended lamivudine therapy, J AIDS, 2006,20: 863-870.
  • 4Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology,2001,34: 1225-1241.
  • 5Benhamou Y, Bochet M, Thibault V, et al. Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients. Hepatology, 1999,30:1302-1306.
  • 6Tenney DJ, Levine SM, Rose RE,et al. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine. J Antimicrob Agents Chemother, 2004, 48:3498-3507
  • 7Levine S, Hernandez D, Yamanaka G, et al. Efficacies of entecavir against lamivudine-resistant hepatitis B virus replication and recombinant polymerases in vitro. Antimicrob Agents Chemother, 2002, 46: 2525-2532.
  • 8Chen RY, Edwards R, Shaw T,et al. Effect of the GI896A precore mutation on drug sensitivity and replication yield of lamivudine-resistant HBV in vitro. Hepatology, 2003, 37 : 27-35.
  • 9Torresi J, Earnest Silveira L,Civitico G,et al. Restoration of replication phenotype of lamivudine~resistant hepatitis B virus mutants by compensatory changes in the " fingers" subdomain of the viral polymerase selected as a consequence of mutations in the overlapping S gene. J Virology, 2002, 299:88-99.
  • 10中华医学会传染病与,寄生虫病学分会,肝病学分会.病毒性肝炎防治方案[J].中华肝脏病杂志,2000,8(6):324-329. 被引量:14007

共引文献1834

同被引文献23

  • 1梁佳佳,张振华,李旭.乙型肝炎病毒核苷(酸)类耐药变异位点检测方法研究进展[J].中华临床感染病杂志,2011,4(6). 被引量:1
  • 2Cai F, Chen H, Gao F, et al. Detection of minor drug-resistancepopulations by parallel allele-specific sequencing[J]. Nat. Methods, 2007, 4:123-125.
  • 3Stephen L. Primary resistance, multidrug resistance, and cross-re- sistance pathways in HBV as a consequence of treatment failure[J]. I-Iepatol Int, 2008, 2:147-151.
  • 4Ma J, Zhang Y, Chen XY, et al. Association of preexisting drug-re- sistance mutations and treatment failure in hepatitis B patients[J]. PLoS One, 2013, 8:e67606.
  • 5Yang JX, Liu BM, Li XG, et al. Profile of HBV antiviral resistance mutations with distincte volutionary pathways against nucleoside/ nucleotide analogue treatment among Chinese chronic hepatitis B patients[J]. Antivir Ther, 2010, 15:1171-1178.
  • 6Delaney WE 4th, Yang H, Westland CE, et al. The hepatitis B virus polymerase mutation rtV173L is selected during lamivudine therapy and enhances viral replication in vitro[J]. J Virol 2003, 77:11833- 11841.
  • 7Tenney DJ, Levine SM, Rose RE, et al. Clinical emergence of ente- cavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine[J]. Antimicrob Agents Che- mother, 2004, 48:3498-3507.
  • 8Zoulim F. Detection of hepatitis B virus resistance to antivirals[J]. J Clin Virol, 2001, 21:243-253.
  • 9刘妍,李庆虹,李乐,施建飞,纪冬,白文林,姚增涛,戴久增,徐东平.慢性HBV感染患者恩替卡韦基因型耐药突变特征分析[J].解放军医学杂志,2010,35(6):621-624. 被引量:15
  • 10金怡,魏飞力,马丽娜,陈新月.PCR产物直接测序法检测乙肝病毒耐药位点的临床研究[J].北京医学,2011,33(12):961-965. 被引量:6

引证文献2

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部